BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp. reported a net loss of $7.2 million attributable to the company for Q2 2026, with a net loss per share of $3.00. The company incurred total operating expenses of $7.5 million, primarily driven by research, development, and clinical trial expenses of $6.1 million. Cash flow from operations was negative $12.9 million, but the company significantly strengthened its liquidity position through financing activities, raising $27.9 million from share issuance and warrant exercises. This resulted in a $19.4 million increase in cash and cash equivalents, ending the period with $29.9 million in cash plus $7.4 million in short-term investments. Total assets stood at $33.6 million against total liabilities of $3.4 million, with shareholders' equity of $30.2 million. The company continues to be in a pre-revenue stage with no disclosed revenue figures for the period.

Key Takeaways